Compare INSG & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSG | TNXP |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.9M | 194.9M |
| IPO Year | 2000 | N/A |
| Metric | INSG | TNXP |
|---|---|---|
| Price | $10.38 | $15.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $15.50 | ★ $70.00 |
| AVG Volume (30 Days) | 181.8K | ★ 492.0K |
| Earning Date | 02-18-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $165,876,000.00 | $10,299,000.00 |
| Revenue This Year | N/A | $2.96 |
| Revenue Next Year | $13.05 | $750.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.24 | $6.76 |
| 52 Week High | $18.11 | $69.97 |
| Indicator | INSG | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 42.05 | 38.66 |
| Support Level | $9.87 | $14.94 |
| Resistance Level | $10.97 | $15.68 |
| Average True Range (ATR) | 0.45 | 0.87 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 38.46 | 10.43 |
Inseego Corp is into the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by applications software and cloud services designed to enable customers to easily analyze data insights and configure and manage their hardware. It generates maximum revenue from United States and Canada. The company also has a presence in Australia and Europe (including United Kingdom).
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.